Document:

EXHIBIT 10.14

        December 11, 2008

        Mr. Stanley Komaroff

        Dear Mr. Komaroff,

        The following is an amendment and restatement of your letter agreement, dated October 10, 2003 (as amended), with Henry Schein, Inc. and sets forth the terms and conditions of your employment with Henry Schein, Inc., effective as of December 11, 2008 (the "EFFECTIVE DATE"). This letter agreement (the "LETTER AGREEMENT") amends and restates any and all prior agreements between you and the Company relating to
        the subject matter hereof.

        
            	
                        1.

                    	
                        Title and Position. You will have the title of Senior Advisor, Member of the Executive Management Committee, or such other title as mutually agreed. Your primary responsibilities shall be devoted to (i) overseeing the Legal Department, (ii) overseeing the Department of Regulatory Affairs, (iii) advising members of the Executive Management Committee, and
                        (iv) becoming involved in business development and any other matters that you are reasonably requested to do by the Chairman or Chief Executive Officer ("CEO") that is commensurate with your position. You will be a member of the Executive Management Committee and report directly to the Chairman and CEO.

                    

        

        
            	
                        2.

                    	
                        Office Location. You will be located at the principal executive offices of the Company, currently located in Melville, New York.

                    

        

        
            	
                        3.

                    	
                        Time Commitment. You will devote at least 75% of your business time to the performance of your duties with the Company. You will be available as necessary at other times, subject to coordination with other commitments.

                    

        

        
            	
                        4.

                    	
                        Term of Contract. Unless either you or the Company give notice to one another, not less than 60 days prior to the end of the Employment Expiration Date (defined below) of an intent not to extend the term, the Employment Expiration Date shall thereafter be automatically extended for additional one-year periods and your employment shall continue on terms
                        substantially similar to the terms contained herein subject to the last sentence of paragraphs 5(a), 5(b) and 5(c) (the "EMPLOYMENT TERM"). Your giving notice referred to in the immediately preceding sentence shall be deemed an election by you to retire under the provisions hereof. The Employment Term shall end upon the termination of your employment for any reason. The date on which the Employment Term is scheduled to end, irrespective of any earlier employment
                        termination, is referred to as the "EMPLOYMENT EXPIRATION DATE."

                    

        

        
            	
                        5.

                    	
                        Compensation.

                    

        

        
            	
                         

                    	
                        a.

                    	
                        Base Salary. Commencing January 1, 2008, as compensation for your employment, you will receive an annual base salary as shall be determined by the CEO, in consultation with the compensation committee of the Board, in all cases payable in accordance with the Company’s normal payroll practices for its senior

                    

        

         

        
            

            
                	
                             

                        	
                            1

                        

            

             

             

            

        

         

        
            

        

         

        executive officers as in effect from time to time (the base salary, as in effect from time to time, is hereinafter referred to as the "BASE SALARY").

        
            	
                         

                    	
                        b.

                    	
                        Equity Compensation. During the Employment Term, you will be eligible to receive annual grants of (i) options to purchase shares of capital stock of the Company, (ii) shares of restricted stock of the Company, and/or (iii) other equity-related awards with respect to shares of capital stock of the Company, in each case, at such times, with the same terms,
                        and in the same manner as applicable to other senior executive officers of the Company, except as modified by the specific provisions set forth in this Letter Agreement. The amount of your equity compensation shall be determined by the CEO, in consultation with the compensation committee of the Board.

                    

        

        
            	
                         

                    	
                        c.

                    	
                        Incentive Compensation. During the Employment Term, you will be eligible to receive, in addition to Base Salary, annual incentive compensation (the "INCENTIVE COMPENSATION"). Your Incentive Compensation may be awarded pursuant to the 2001 Henry Schein, Inc. Section 162(m) Cash Bonus Plan (the "162(M) PLAN") or any
                        another annual incentive compensation plan maintained by the Company. All Incentive Compensation shall be paid as soon as practicable after the amount of such compensation has been finally determined, and in all events during the calendar year immediately following the calendar year with respect to which the Incentive Compensation was earned. Your Incentive Compensation shall be determined by the CEO, in consultation with the compensation committee of the Board, except
                        as may be required by law or the terms and conditions of the 162(m) Plan, in which case the Incentive Compensation shall be determined by the compensation committee of the Board.

                    

        

        
            	
                         

                    	
                        d.

                    	
                        Expenses. The Company will reimburse you for all expenses you reasonably incur in the performance of your duties with the Company, in accordance with the Company's general policies and practices for senior executive officers in effect from time to time; provided that in no event shall any such reimbursement be made later than the later of (i) the
                        15th day of the third month following the end of the calendar year in which the applicable expense is incurred or (ii) the 15th day of the third month following the end of the fiscal year in which the applicable expense is incurred.

                    

        

        
            	
                         

                    	
                        e.

                    	
                        Benefits. During the Employment Term, you will be entitled to participate in all benefit, welfare, perquisite, equity and other similar plans, policies and programs, in accordance with the terms thereof, as are generally provided from time to time by the Company for its senior executive officers and for which you are eligible. To the extent that any benefit
                        offered from time to time by the Company to its senior executive officers generally is not available to you, by reason of age, you will receive an amount of cash equal to the amount it would have cost the Company to provide such benefit at the highest age for which it could be provided, and such cash payment shall be made no later than the later of (i) the 15th day of the third month following the end of the calendar year in which the benefit is offered to
                        senior executive officers or (ii) the 15th day of the third month following the end of the fiscal year in which the benefit is offered to senior executive officers.

                    

        

         

        
            

            
                	
                             

                        	
                            2

                        

            

             

             

            

        

         

        
            

        

        
             
        

        
            	
                         

                    	
                        f.

                    	
                        Vacation. During each calendar year during the Employment Term, you will be entitled to four weeks of vacation and such other number of personal days generally afforded to senior executives of the Company.

                    

        

        
            	
                         

                    	
                        g.

                    	
                        Automobile Allowance. During the Employment Term, the Company will provide you with an automobile allowance of $18,000 per year payable in 12 substantially equal monthly installments, which amount will increase to the extent that the automobile allowances of other senior executive officers increase.

                    

        

        
            	
                         

                    	
                        h.

                    	
                        Change in Control Agreement. You will be covered by a change in control agreement in the same form as that applicable to other senior executive officers of the Company.

                    

        

        
            	
                        6.

                    	
                        Employment Termination.

                    

        

        
            	
                         

                    	
                        a.

                    	
                        Death; Disability. If your employment hereunder is terminated by reason of your death or Disability (as defined below), the Company will have no further obligation to you under this Letter Agreement except that you (or your heirs or estate, if applicable) will be paid those obligations accrued hereunder to the date of your employment termination, consisting
                        only of (i) any unpaid Base Salary to the extent unpaid through the date of termination, which will be paid to you in a lump sum within 15 days after your employment termination, (ii) any deferred compensation earned but not yet paid (together with any accrued earnings thereon), which will be paid in accordance with the payment provisions of the applicable plan(s), (iii) any annual Incentive Compensation due to you for the last full fiscal year of the Company ending
                        prior to the date of termination (if not previously paid) which shall be paid no later than the time specified in the last sentence of Section 5(c) above, (iv) the product of (A) the annual Incentive Compensation actually payable to you for the current fiscal year of the Company, multiplied by (B) a fraction, the numerator of which is the number of days in such fiscal year during which you were employed by the Company, and the denominator of which is 365 (such amount to
                        be paid to you when and as such Incentive Compensation is paid to senior executive officers of the Company generally, but no later than the time specified in the last sentence of Section 5(c) above), (v) to the extent consistent with Company policy, any accrued and unpaid vacation pay and payment for unreimbursed expenses, which will be paid to you in a lump sum within 15 days after your termination of employment, and (vi) any other amounts or benefits owing to you or
                        your beneficiaries under the then applicable benefit plans, policies and programs of the Company with respect to senior executive officers, which will be paid to you in accordance with the payment provisions of such benefits plans, policies or programs. (All amounts determined pursuant to the provisions of in clauses (i) through (vi) above are hereinafter referred to as the "ACCRUED OBLIGATIONS"). Upon such employment termination, if and to the extent provided to members
                        of senior management, you will vest in equity-related awards with respect to shares of Company capital stock previously granted to you, and such awards will remain exercisable following termination, in each case to the extent provided or to be provided to members of senior management; provided, however, that the post-termination exercise period with regard to stock options will be at least three years (but not beyond the original term of such awards). Nothing herein will
                        be

                    

        

         

        
            

            
                	
                             

                        	
                            3

                        

            

             

             

            

        

         

        
            

        

         

        deemed to limit or expand in any way the right of your family to receive any death or disability benefit payable to them pursuant to any insurance policy. For purposes of this Letter Agreement, "DISABILITY" means your employment termination by the Company following your inability to perform your material duties for 180 days in any 365-day period due to your physical or mental incapacity.
        During any period of such incapacity, you will continue to receive all compensation and other benefits provided herein as if you had not been incapacitated at the time, in the amounts and in the manner provided herein, provided that the Company will be entitled to a credit against such amounts with regard to the amount, if any, paid to you for such period under any disability plan of the Company. Notwithstanding the foregoing, in the event your termination of employment is due to your
        Disability, any amounts payable to you as set forth above, will not be paid earlier than the day following the six-month anniversary of your termination of employment.

        
            	
                         

                    	
                        b.

                    	
                        Company Termination for Cause or Resignation Other Than for Good Reason (except Retirement). If your employment hereunder is terminated by the Company for Cause or you resign without Good Reason (other than Retirement), the Company will have no further obligation to you under this Letter Agreement, except that, unless otherwise required by any employee
                        benefit plan, you will be paid all Accrued Obligations to the date of termination in accordance with such time periods and the payment provisions set forth in 6(a) above. Notwithstanding the preceding sentence, in the event of a termination by the Company for Cause or a resignation by you without Good Reason (other than Retirement), you will not be entitled to receive the payments specified in paragraphs 6(a)(iii) and (iv) above. For purposes of this Letter Agreement,
                        "GOOD REASON" means (i) any diminution in title or material diminution in your position, duties, responsibilities or authority (except by reason of physical or mental incapacity or approved leave of absence), or assignment to you of duties or responsibilities that are materially inconsistent with your position at the time of such assignment, or (ii) any material breach by the Company of this Letter Agreement (including failure of successor to assume contractual duties in
                        writing) not cured within 15 days after written notice thereof is given by you to the Company, and "CAUSE" means (i) an action or omission by you involving willful malfeasance or willful misconduct having a material adverse effect (whether economic or as to reputation) on the Company, (ii) your conviction of, or pleading nolo contendere to, a felony (other than resulting from a traffic violation or like event) or your conviction of any other crime involving intentional
                        dishonesty or fraud, or (iii) any other action by you constituting a material breach of your employment that is not cured within 15 days after notice from the Company thereof. In the case of clause (i) of this Cause definition, no act or omission by will be considered willful if it is done or omitted in good faith and with a reasonable belief that it was in the best interests of the Company.

                    

        

        
            	
                         

                    	
                        c.

                    	
                        Company Termination Without Cause; Resignation for Good Reason; Non-Renewal. If your employment hereunder is terminated by the Company without Cause, if you resign for Good Reason, or if the Company provides you with a non-renewal notice, the Company will have no further obligation to you under this Letter Agreement except that:

                    

        

         

        
            

            
                	
                             

                        	
                            4

                        

            

             

             

            

        

         

        
            

        

        
             
        

        
            	
                         

                    	
                        i.

                    	
                        Unless otherwise required by an employee benefit plan, you will be paid all Accrued Obligations to the date of termination in accordance with such time periods and the payment provisions set forth in 6(a) above.

                    

        

        
            	
                         

                    	
                        ii.

                    	
                        If your employment hereunder is terminated by the Company without Cause, if you resign for Good Reason or if the Company provides you with a notice of non-renewal, in each case, with respect to any period occurring prior to January 1, 2010, you will be paid as severance pay, (A) one times your Base Salary, payable in a lump sum in cash on the first business
                        day immediately following the six-month anniversary of your employment termination date and (B) 100% of your prior year’s incentive bonus, payable in cash within 30 business days after the calculation. Notwithstanding the foregoing, if your employment hereunder is terminated by the Company without Cause, if you resign for Good Reason or if the Company provides you with a non-renewal notice, in each year, with respect to any period after December 31, 2009, the
                        Company shall have no severance pay obligations to you under this Letter Agreement.

                    

        

        
            	
                         

                    	
                        iii.

                    	
                        If your employment is terminated with Cause, any unvested stock options shall not vest and shall be forfeited.

                    

        

        
            	
                         

                    	
                        d.

                    	
                        Retirement. If your employment terminates by reason of resignation without Good Reason ("RETIREMENT"), the Company will have no further obligation to you under this Letter Agreement, except that, unless otherwise required by any employee benefit plan and except as expressly set forth herein, you will be paid all Accrued Obligations to the date of
                        termination.

                    

        

        
            	
                         

                    	
                        e.

                    	
                        Termination Other Than for Cause or Due to Death or Disability. If your employment terminates for any reason by you or the Company other than for Cause or due to death or Disability, then (i) such termination of employment will be treated as a retirement under all equity plans, (ii) any shares of Company capital stock or other equity-based awards (other
                        than stock options) previously granted to you and subject to restrictions will immediately vest in full, except that such shares or equity-based awards shall continue to be subject to any performance-based restrictions set forth in the applicable award agreement, and (iii) any stock options to purchase shares of capital stock of the Company previously granted to you will continue to vest (as scheduled) for 30 months following Retirement (at which time all unvested stock
                        options will vest in full) and will remain exercisable for at least three years following such termination, but not beyond the original term of such awards. The terms of this section shall apply to all equity awards, whether heretofore or hereafter granted.

                    

        

        
            	
                         

                    	
                        f.

                    	
                        Other. Notwithstanding the foregoing, upon your termination of employment from the Company for any reason whatsoever, you will retain your rights to indemnification as set forth in Section 10 of this Letter Agreement.

                    

        

        
            	
                        7.

                    	
                        Treatment of Equity Due to Post-Termination Service. Notwithstanding anything to the contrary contained herein, if you serve as a director or consultant to the Company following your employment termination, equity-related awards with respect to shares of Company capital stock previously granted to you will continue to be exercisable, and, to the extent not
                        fully vested, will continue to vest, in each case during such period, and any

                    

        

         

        
            

            
                	
                             

                        	
                            5

                        

            

             

             

            

        

         

        
            

        

         

        stock options vested at the conclusion of such period shall remain exercisable for the period specified herein upon the applicable termination of employment, but measured from the cessation of such consulting or directorship (as the case may be), but not beyond their original term.

        
            	
                        8.

                    	
                        Confidential Information; Noncompetition; Etc.

                    

        

        
            	
                         

                    	
                        a.

                    	
                        Both during and after the Employment Term, you will hold in a fiduciary capacity for the benefit of the Company and will not, without the prior written consent of the Company, communicate or divulge (other than in the regular course of the Company's business), to anyone other than the Company, its subsidiaries and those designated by it, any confidential or
                        proprietary information, knowledge or data relating to the Company or any of its subsidiaries, or to any of their respective businesses, obtained by you before or during the Employment Term except to the extent (i) disclosure is made during the Employment Term by you in the course of your duties hereunder and you reasonably determine in good faith that it is in the best interest of the Company to do so, (ii) you are compelled pursuant to an order of a court or other body
                        having jurisdiction over such matter to do so (in which case the Company shall be given prompt written notice of such intention to so divulge not less than five days prior to such disclosure or such shorter period as the circumstances may reasonably require) or (iii) such information, knowledge or data is or becomes public knowledge or is or becomes generally known within the Company's industry other than through improper disclosure by you.

                    

        

        
            	
                         

                    	
                        b.

                    	
                        You acknowledge and agree that the whole interest in any invention, improvement, confidential information, copyright, design, plan, drawing or data, including all worldwide rights to copyrights or any other intellectual property rights (collectively, the "RIGHTS") arising out of or resulting from performance of your duties during the Employment Term shall
                        be the sole and exclusive property of the Company. You undertake (at the expense of the Company) to execute any document or do any reasonably necessary act to enable the Company to obtain or to assist the Company in obtaining any Rights. You hereby irrevocably appoint the Company to be your attorney-in-fact to execute in your name and on your behalf any instrument required and take any actions reasonably necessary for the purpose of giving to the Company the full benefit
                        of the provisions of this subsection; provided, however, that the Company shall notify you prior to executing any such instruments or taking any such actions.

                    

        

        
            	
                         

                    	
                        c.

                    	
                        You will not (other than on behalf of the Company) directly or indirectly during the Employment Term, as an individual proprietor, partner, stockholder, officer, employee, director, joint venturer, investor, lender, or in any other capacity whatsoever (other than as the holder of not more than one percent of the total outstanding stock of a publicly held
                        company) engage in any activity competitive with a material segment of the business of the Company. We recognize that you may serve on the boards of directors of one or more hospitals that are customers of the Company. You may serve on any such boards (including as the nonexecutive chairman or vice chairman of any such board), but you shall abstain from being involved in any purchase decisions with regard to the Company or products of a type the Company sells.

                    

        

         

        
            

            
                	
                             

                        	
                            6

                        

            

             

             

            

        

         

        
            

        

        
             
        

        
            	
                         

                    	
                        d.

                    	
                        If any restriction set forth in this section is found by any court of competent jurisdiction or arbitrator to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic
                        area as to which it may be enforceable.

                    

        

        
            	
                         

                    	
                        e.

                    	
                        The restrictions contained in this section are necessary for the protection of the business and goodwill of the Company and are considered by you to be reasonable to such purpose. You acknowledge and agree that money damages would not adequately compensate the Company for any breach of this section, which would cause the Company substantial and irreparable
                        damage. Therefore, in the event of any such breach, in addition to such other remedies which may be available, the Company shall have the right to seek specific performance and injunctive relief.

                    

        

        
            	
                        9.

                    	
                        No Mitigation; No Set-Off. The Company agrees that if your employment with the Company is terminated prior to the Employment Expiration Date for any reason whatsoever, you are not required to seek other employment or to attempt in any way to reduce any amounts payable to you by the Company pursuant to this Letter Agreement. Further, the amount of any
                        payment provided for in this Letter Agreement shall not be reduced by any compensation earned by you as the result of employment by another employer or otherwise. The Company's obligations to make the payments provided for in this Letter Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, or other similar right that the Company may have against you.

                    

        

        
            	
                        10.

                    	
                        Indemnification. The Company will indemnify you (or, in the event of your death, your heirs, executors, administrators or legal representatives) and hold you harmless, in each case to the fullest extent permitted by the by-laws of the Company, against and in respect to any and all actions, suits, proceedings, claims, demands, judgments, costs, expenses
                        (including attorney's fees), penalties, fines, settlements, losses, and damages resulting from, or in connection with, your employment with the Company, including but not limited to as an officer and director of any subsidiary or parent or as a fiduciary of any employee benefit plan. The Company will cover you under directors and officers liability insurance both during and after the termination or expiration of the Employment Term in the same amount and to the same
                        extent as the Company covers its other senior executive officers and directors.

                    

        

        
            	
                        11.

                    	
                        No Assignments. This Letter Agreement is personal to each of the parties hereto. Except as provided in the next sentence, no party may assign or delegate any rights or obligations hereunder without first obtaining the written consent of the other party hereto. As used in this Letter Agreement, the "Company" shall mean the Company and any successors or
                        assigns. This Letter Agreement shall inure to the benefit of and be enforceable by you and your personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If you should die while any amount would still be payable to you hereunder had you continued to live, all such amounts, unless otherwise provided herein, will be paid in accordance with the terms of this Letter Agreement to your estate.

                    

        

         

        
            

            
                	
                             

                        	
                            7

                        

            

             

             

            

        

         

        
            

        

        
             
        

        
            	
                        12.

                    	
                        Section Headings. The section headings used in this Letter Agreement are included solely for convenience and shall not affect, or be used in connection with, the interpretation of this Letter Agreement

                    

        

        
            	
                        13.

                    	
                        Code Section 409A. It is intended that the provisions of this Letter Agreement comply with, or be exempt from, Section 409A of Internal Revenue Code of 1986 (as amended) and the regulations and guidance promulgated thereunder (collectively "CODE SECTION 409A"), and all provisions of this Letter Agreement shall be construed in a manner consistent with the
                        requirements for avoiding taxes or penalties under Code Section 409A. Notwithstanding the foregoing, the Company does not guarantee any particular tax treatment and the Company shall have no liability with regard to any failure to comply with Code Section 409A. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Letter Agreement providing for the payment of any amounts or benefits, which are subject to Code Section 409A,
                        upon or following a termination of employment, unless such termination is also a "separation from service" within the meaning of Code Section 409A (and the guidance issued thereunder) and, for purposes of any such provision of this Letter Agreement, references to a "resignation," "termination," "termination of employment," "retirement" or like terms shall mean separation from service.

                    

        

        
            	
                        14.

                    	
                        Miscellaneous. This Letter Agreement, together with any exhibits hereto (including the change of control agreement), sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein, and this Letter Agreement supersedes any prior written understanding entered into between the parties with respect to the subject matter
                        hereof. No agreements or representations, oral or otherwise, express or implied, which are not expressly set forth in this Letter Agreement, have been made by either party with respect to the subject matter hereof. The validity, interpretation, construction and performance of this Letter Agreement shall be governed by the laws of the State of New York applicable to agreements made and to be performed entirely within such State.

                    

        

        
            	
                        15.

                    	
                        Counterparts. This Letter Agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instruments.

                    

        

        We look forward to having you at the Company. If you find the terms of this Letter Agreement acceptable, please sign below and return it to me.

         

        
            

            
                	
                             

                        	
                            8

                        

            

             

             

            

        

         

        
            

        

         

        Very truly yours,

        Henry Schein, Inc.

        Agreed and accepted:

        
            	
                        By

                    	
                        /s/ Stanley M. Bergman

                    
	
                         

                    	
                        STANLEY BERGMAN

                    
	
                         

                    	
                        EXECUTIVE CHAIRMAN

                    
	
                         

                    	
                        AND CHIEF EXECUTIVE OFFICER

                    

        

         

        Agreed and accepted: 

        
            	
                        /s/ Stanley Komaroff

                    
	
                        STANLEY KOMAROFF

                    

        

         

         

         

        
            

            
                	
                             

                        	
                            9EXHIBIT 10.20

             

            Portions of this agreement have been omitted and separately filed with the SEC with a request for confidential treatment. The location of those omissions have been noted by [**].

             

            

        

         

        AMENDMENT TO DISTRIBUTON AGREEMENT

        FOR FLUVIRALTM (INFLUENZA VACCINE)

         

        THIS AMENDMENT is entered into as of the October 2, 2006, by and between ID Biomedical Corporation (“IDB”) and Henry Schein, Inc. (“HSI”) (the “Amendment”).

         

        WHEREAS, HSI and IDB have entered into a certain Distribution Agreement for FluviralTM influenza vaccine as of December 2, 2004 (“Agreement”);

         

        WHEREAS, in December 2005, IDB became a wholly-owned subsidiary of GlaxoSmithKline Inc, a wholly-owned subsidiary of GlaxoSmithKline plc and an Affiliate of SmithKline Beecham Corporation d/b/a GlaxoSmithKline (“GSK”);

         

        WHEREAS, IDB has informed HSI that Marketing Authorization for Product in the Territory will not be received prior to April 1, 2006 and that the manufacture and delivery of some portion of the Product for the 2006/2007 Flu Season will occur after [**], and IDB and HSI desire to amend the Agreement as set forth below in this Amendment.

         

        NOW, THEREFORE, in consideration of the mutual covenants contained hereto, the parties, intending to be legally bound, agree to amend the Agreement to accommodate certain revisions for the 2006/2007 Flu Season as follows:

         

        This Amendment applies to the 2006/2007 Flu Season only.

         

        
            	
                        1.

                    	
                        Section 1.20 is hereby amended to add the following new first sentence to the beginning thereof:

                    

        

         

        “1.20“Territory” for the 2006/2007 Flu season shall mean the United States of America, including all fifty states, the District of Columbia (excluding Puerto Rico and any U.S. possessions and territories).”

         

        
            	
                        2.

                    	
                        Section 2.3 is hereby amended and restated in its entirety to read as follows:

                    

        

         

        “2.3 As Product distributor, HSI shall determine the prices and other terms and conditions under which it offers Product for sale and sells Product to customers within the Territory. On or prior to the Commencement Date, HSI shall provide IDB with a resale certificate in such form, and containing such information, as required by IDB. On a monthly basis during
        the Term, beginning after the Commencement Date, HSI shall provide a detailed written report to IDB, in a mutually agreeable format, describing forecast and actual Product sales for a given Flu season, broken down by customer segment and type of Product [**] and other reasonably relevant information requested by IDB. Such report shall also include information IDB may request to allow IDB or any of its Affiliates to comply with any government reporting obligations IDB or such Affiliates
        may have pertaining to sales of Product. IDB shall have the right to have all or a portion of the information contained in the monthly report provided to an independent third party reviewer selected by IDB (the “Auditor”) in lieu of the information being provided directly to IDB. In addition, for purposes of monitoring compliance with Section 6.1, HSI shall also provide, either as part of the monthly report or, at the election of IDB, in a separate report provided at the
        same time as the monthly report to the Auditor, information and data, as reasonably requested by IDB and/or its Auditor, [**], HSI shall deliver the monthly reports to IDB or the Auditor (if directed

         

        

        
            	
                         

                    	
                        [**] - Confidential or proprietary information redacted.

                    

        

        

         

        
            

        

         

         

        by IDB) prior to the monthly meetings conducted pursuant to Section 6.3, and, if IDB elects to have the [**] data provided to the Auditor rather than to IDB, HSI shall deliver such separate report to the Auditor at the same time it delivers the monthly report to IDB. IDB will require the Auditor to maintain the confidentiality of any information provided to it in accordance with
        obligations of IDB under Section 9 of the Agreement. IDB will bear the expenses of any outside auditor it elects to use under this provision. Notwithstanding the foregoing, HSI shall not be required to identify names or address of customers of Product or [**] and shall not be required to provide information which HSI is prohibited by contract or law from providing to third parties. HSI shall report its sales of Product and competing products where applicable, to IMS Health (DDD) or
        another third-party data vendor.”

         

        
            	
                        3.

                    	
                        Section 2.5 is hereby amended to add the following new second, third and fourth sentences:

                    

        

         

        “2.5 For the 2006/2007 Flu Season, IDB shall have the right to make available through a Federal Supply Schedule contract of IDB or one or more of its Affiliates (the “FSS Contract”) up to one percent (1%) of the total doses of Product it makes available for sale or distribution for the 2006/2007 Flu Season. IDB shall inform HSI in writing of the
        amount it intends to make available through the FSS Contract for the 2006/2007 Flu Season no later than [**]. In the event IDB supplies Product to any United States government agency or body or supplies Product through the FSS Contract pursuant to this Section, the Minimum Quantity of HSI’s pro rata share of doses shall be reduced by such amount for the 2006/2007 Flu Season.”

         

        
            	
                        4.

                    	
                        The following language is inserted before the existing second sentence of Section 3.1:

                    

        

         

        “For the 2006/2007 Flu Season, HSI hereby commits to purchase the Minimum Quantity of Product provided by IDB to HSI for the 2006/2007 Flu Season for the Purchase Price described in Schedule 1 (plus the Federal Excise Taxes described in Section 4.1) for all of Product delivered to HSI’s warehouses CBER released and available for sale to customers by [**]
        for the 2006/2007 Flu Season. For any Product delivered to HSI’s warehouses, CBER released and available for sale to customers after [**] and on or before [**] (hereinafter “November Product”):

         

        (a) [**] percent ([**]%) of the November Product shall be shipped on a non-returnable basis except as set forth in Sections 3.7 and 5.3 and except if there is a Product recall. The remaining [**] percent ([**]%) of the November Product will be returnable. In the event that IDB fails to deliver to HSI’s warehouses (CBER released and available for sale) [**] percent ([**]%) of the
        total doses delivered in [**], any such the shortfall shall also be returnable. Solely for purposes of the calculation of whether any additional doses are returnable in accordance with the previous sentence, if doses scheduled for delivery in November under Schedule 1 are delivered ahead of schedule in October, such doses shall be counted as having been delivered in November and prior to [**]. IDB shall use commercially reasonable efforts to distribute the November Product in
        approximately equal weekly allotments during the month of November (or IDB shall, if practicable, accelerate weekly allotments to supply November Product as early as practicable during such month). For any Product to be delivered and released after [**], HSI hereby declines to exercise its rights to receive such doses under Section 3.7 and IDB may sell any such doses on its own. In the event that doses are available for delivery and release in December and IDB is able to find a
        purchaser for such doses and requires distribution services, HSI hereby agrees to provide distribution services in connection with the sales of such doses and to charge the end use customer no more than the price negotiated by IDB with the end user customer (HSI may charge less if it elects to do so), and HSI shall pay IDB for such doses the Purchase Price set for in Section 2(A)(v) of Schedule 1 of the Agreement. Such doses shall not be part of the Minimum Quantity and shall not count
        towards the calculation of Average Selling Price or in other

         

        
            

            
                	
                             

                        	
                            [**] - Confidential or proprietary information redacted.

                        

            

             

            

        

         

        
            

        

         

         

        calculations, however, the normal terms for the purchase and sale of Product contained in this Agreement (e.g., terms of sale, payment terms, etc.) shall apply;

         

        (b) as an alternative to HSI purchasing the November Product under the terms and conditions of subsection (a) of this provision, HSI may, by providing written notice to IDB by [**], elect to take delivery of and purchase only a portion of the product available for delivery and release in November and such product shall be sold on a non-returnable basis, except as set forth in Sections 3.7
        and 5.3, and except if there is a Product recall. Any written notice from HSI must specify the amount of Product it elects to purchase for delivery and release in November and a requested delivery schedule that is consistent with the estimated delivery schedule described in subsection (a) above, and IDB shall use commercially reasonable efforts to distribute product in accordance with such proposed delivery schedule. For any Product available for delivery and release in November that
        HSI elects not to take under this provision and for Product to be delivered and released after [**], HSI hereby declines to exercise its rights to receive such doses under Section 3.7 and IDB may sell any such doses on its own. In the event that such doses are available for delivery and release in November or December and IDB is able to find a purchaser for such doses and requires distribution services, HSI hereby agrees to provide distribution services in connection with the sales of
        such doses and to charge the end use customer no more than the price negotiated by IDB with the end user customer (HSI may charge less if it elects to do so), and HSI shall pay IDB for such doses the Purchase Price set forth in Section 2(A)(v) of Schedule 1 of the Agreement. Such doses shall not be part of the Minimum Quantity and shall not count towards the calculation of [**] or in other calculations, however, the normal terms for the purchase and sale of Product contained in this
        Agreement (e.g., terms of sale, payment terms, etc.) shall apply.”

         

        
            	
                        5.

                    	
                        Section 3.6 is hereby amended by adding the following sentence at the end thereof:

                    

        

         

        “Notwithstanding the foregoing, prior to the initial Marketing Authorization and during the 2006/2007 Flu Season, IDB or an Affiliate will be the importer of record of Product into the Territory. During the 2006/2007 Flu Season, Product will be shipped to a GSK warehouse in [**] or [**] prior to reshipment to HSI.”

         

        
            	
                        6.

                    	
                        The following new sentence is inserted before the existing third sentence of Section 3.7:

                    

        

         

        “However, IDB shall use its commercially reasonable efforts to obtain the necessary Regulatory Authority releases to the extent reasonably possible by the delivery dates set forth in Section 1 of Schedule 1 for the 2006/2007 Flu Season; provided, that, if and to the extend that the Product is not manufactured or
        available for release, or that some or all Regulatory Authority releases are not obtained, on or before either the delivery schedule in Section 1 of Schedule 1 for the 2006/2007 Flu Season, irrespective of the reason therefore, (i) IDB shall not be deemed to have breached any obligations under this Agreement or be liable to HSI hereunder provided that IDB has used it commercially reasonable efforts to obtain necessary Regulatory Authority releases as soon as reasonably possible for the
        2006/2007 Flu Season, and (ii) notwithstanding the provisions of Section 10 below, if one hundred percent (100%) of the Minimum Quantity of Product is not released by [**] of the 2006/2007 Flu Season, then HSI hereby declines to exercise its rights to purchase the amount of Product that was not released by such date and all such doses shall be excluded from the Minimum Quantity for the 2006/2007 Flu Season as further provided in Section 3.1.”

         

        
            	
                        7.

                    	
                        Section 4.1 is hereby amended by adding the following sentence at the end thereof:

                    

        

         

        
            

            
                	
                             

                        	
                            [**] - Confidential or proprietary information redacted.

                        

            

             

            

        

         

        
            

        

         

         

        “In addition to the Purchase Price, for the 2006/2007 Flu Season, HSI shall also pay IDB all applicable Federal excise taxes in effect on the date of IDB’s shipment of Product to HSI (the “Federal Excise Taxes”).”

         

        
            	
                        8.

                    	
                        Section 5.1 is hereby amended by adding the following sentence to the beginning thereof:

                    

        

         

        “5.1 IDB agrees to deliver all Product for the 2006/2007 Flu Season ordered by HSI in accordance with Section 5.5.”

         

        
            	
                        9.

                    	
                        Section 5.2 is hereby amended by adding the following after the first sentence thereto:

                    

        

         

        “For the 2006/2007 Flu Season, all Product is shipped on a non-returnable basis except only as set forth in Sections 3.1, 3.7 and 5.3 and except if there is a Product recall.”

         

        
            	
                        10.

                    	
                        Section 5.4 is hereby amended by deleting the term “[**]” wherever it appears in Section 5.4 with respect to the 2006/2007 Flu Season and replacing each such term with the following terms:

                    

        

         

        “[**] of the 2006/2007 Flu Season.”

         

        
            	
                        11.

                    	
                        Section 5.5 is hereby amended to add the following sentence to the end thereof:

                    

        

         

        “For the 2006/2007 Flu Season, HSI shall handle and store Product in a clean and orderly location and in a manner, which will assure that the quality of the Product is maintained. HSI shall comply with GSK criteria on proper storage and shipping of Product as provided in Addendum I attached to this Amendment and incorporated by reference herein.” To the
        extent HSI incurs additional out-of-pocket costs in the 2006/2007 Flu Season in connection with the use of the TagAlert required by Addendum 1 over and above those costs HSI would have incurred in using the system it currently uses to maintain appropriate temperature for Product it ships, IDB will reimburse HSI for such costs up to a maximum amount of $[**]. HSI shall provide reasonable documentation for any reimbursement for such additional costs and IDB shall have the right to review
        those costs.

         

        
            	
                        12.

                    	
                        Section 7.2 is hereby amended and restated in its entirety as follows:

                    

        

         

        “7.2 If IDB receives the initial Marketing Authorization on or before [**], the Commencement Date shall be the date of the initial Marketing Authorization. With respect to the 2006/2007 Flu Season, If IDB receives the initial Marketing Authorization by [**], then HSI shall have the obligation to purchase the Minimum Quantity of Product for the 2006/2007 Flu
        Season as set forth in Schedule 1. If IDB receives the initial Marketing Authorization after [**], then HSI shall have no obligation to acquire Product for the 2006/2007 Flu Season, unless the Parties otherwise agree in writing.

         

        
            	
                        13.

                    	
                        The last sentence of Section 7.5 of the Agreement shall be deleted and replaced with the following:

                    

        

         

        “For the 2006/2007 Flu Season, HSI recognizes and understands that IDB, as a pharmaceutical company, is subject to certain federal, state and local laws and regulations governing the promotion and marketing of prescription drugs and as such IDB needs to control tightly any such promotional or marketing activities in accordance therewith. To the extent required,
        IDB shall provide to HSI promotional or marketing materials for the Product. HSI shall not use any promotional or marketing materials or revise and use any IDB created promotional or marketing

         

        
            

            
                	
                             

                        	
                            [**] - Confidential or proprietary information redacted.

                        

            

             

            

        

         

        
            

        

         

         

        materials, unless such materials have first been submitted to and approved by IDB in advance in writing.”

         

        
            	
                        14.

                    	
                        Schedule 1 to the Agreement is amended as follows:

                    

        

         

        
            	
                         

                    	
                        a.

                    	
                        In Section 1 of the Schedule, the introductory clause in the first three lines under the heading

                    

        

        “Total Minimum Quantity per Flu Season” is amended to read as follows:

         

        “Subject to reduction of the Minimum Quantity as provided in Sections 2.5, 3.1, 3.2, 3.7, 3.9 and 7.4 of the Agreement,”

         

        
            	
                         

                    	
                        b.

                    	
                        In Section 1 of the Schedule, under the heading “Delivery Date per Flu Season,” the paragraph is amended to add the following new sentence:       

                    

        

         

        “For the 2006/2007 Flu Season, the foregoing percentages of Minimum Quantity and respective delivery dates shall not apply. As of the date of this Amendment, IDB estimates it will have delivered to distributors’ warehouses by [**] a total of approximately [**] doses which will be CBER released and available for sale by such date (approximately [**]% of the total doses
        anticipated to be available by [**]) and will deliver to distributors’ warehouses by [**] an additional approximately [**] doses, which will be CBER released and available for sale by such date (approximately [**]% of the total doses anticipated to be available by [**]). HSI’s respective portion of these doses shall be the Minimum Percentage (approximately [**] doses estimated to be Delivered to HSI’s warehouses CBER released and available for sale by [**] and another
        approximately [**] doses estimated (if HSI elects the terms of Section 3.1(a) above) or the reduced amount (if HSI elects the terms of Section 3.1(b) above) to be delivered to HSI’s warehouses, CBER released and available for sale by [**]. IDB will use commercially reasonable efforts to deliver and obtain releases for HSI’s doses by the dates set forth above.”

         

        
            	
                         

                    	
                        c.

                    	
                        Section 2(A) (iv) of the Agreement is hereby amended by adding the follow at the end thereof:

                    

        

         

        “Notwithstanding the foregoing, for the 2006/2007 Flu Season only, with respect to all doses of Product sold by HSI to Other Distributors as permitted under Paragraph 3 of this Schedule 1 below, HSI shall pay IDB [**].”

         

        
            	
                         

                    	
                        d.

                    	
                        Section 2(A) of the Agreement is hereby amended by adding the following paragraph at the end thereof:

                    

        

         

        “(v) With respect to Product sold to HSI in December 2006 for resale to customers for which IDB has requested distribution services as provided in Section 3.1 of the Agreement, HSI shall pay IDB [**].”

         

        
            	
                         

                    	
                        e.

                    	
                        In Section 3 of the Schedule, under the heading “Resale to Other Distributors”, the following new first sentence is added to the beginning thereof:

                    

        

         

        “The foregoing limits on the amount of Product HSI may resell to Other Distributors for further sale or distribution shall not apply to the 2006/2007 Flu Season.”

         

        All remaining terms and conditions of the Agreement not expressly amended herein shall remain in full force and effect.

         

        
            

            
                	
                             

                        	
                            [**] - Confidential or proprietary information redacted.

                        

            

             

            

        

         

        
            

        

         

         

        In the event of a conflict between any of the terms contained in this Amendment and the terms contained in the Agreement, the terms of the Amendment shall govern.

         

        All defined terms and conditions not expressly defined herein shall have the meaning ascribed to such terms in the Agreement.

         

        If this Agreement is not signed and returned on or by the date on which IDB notifies HSI of IDB’s receipt of the Initial Marketing Authorization, then IDB withdraws this proposal and the proposed terms and conditions contained herein.

         

        IN WITNESS WHEREOF, the parties have executed this Amendment as of the date last written below.

         

         

        
            	
                                      ID Biomedical Corporation

                    	
                        Henry Schein, Inc.

                    

        

         

         

         

        
            	
                                     By:        /s/ Paul Pinsonnault

                    	
                        By:       /s/ Michael Racioppi

                    
	
                                     Title:      Secretary

                    	
                        Title:    President Medical Group

                    
	
                         

                    	
                         

                    
	
                                     Date:     10/03/06

                    	
                        Date:     10/2/06

                    

        

         

         

         

         

         

         

         

         

         

        
            

            
                	
                             

                        	
                            [**] - Confidential or proprietary information redacted.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00153-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00153-of-00352.parquet"}]]